Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Anticancer Agents Med Chem ; 19(15): 1863-1873, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30973113

RESUMO

BACKGROUND: Liver cancer is a life threating disease as it is the fifth most common cancer and the third most common cause of death worldwide with no safe, efficient, and economic drug available for treatment. METHODS: This study intended to investigate glycyrrhizin and its derivatives for possible use as a cytotoxic agent and as a drug for liver cancer treatment. Thus, after treatment of liver cancer cell line HepG-2 with 50 µM of each compound, cell viability was determined. RESULTS: The cytotoxicity assay showed glycyrrhizin derivatives ME-GA (18ß-Glycyrrhetinic-30-methyl ester) and AKBA (3-acetyl-11- keto-ß-Boswellic acid) to be the most potent drug against liver cancer cell line HepG-2 with IC50 values 25.50 ± 1.06 and 19.73 ± 0.89 µM, respectively. Both the compounds showed higher selectivity towards hepatocellular carcinoma rather than the normal lung fibroblast cell line WI-38. The presence of methyl ester at C-30 greatly increased the cytotoxicity of ME-GA which might be attributed to its higher activity and selectivity. Both ME-GA and AKBA contributed to inhibit cancer cell migration in the wound healing assay and impeded colony formation. The use of flow cytometry to carry out cell cycle analysis and the determination of possible mechanisms of action for apoptosis revealed that ME-GA arrested the cell cycle at G2/M that led to the inhibition of hepatocellular carcinoma and induced apoptosis via the extrinsic pathway and its ability to increase p53 transactivation. CONCLUSION: This work highlights the cytotoxicity of glycyrrhizin and its derivatives for possible use as a chemotherapeutic agent against hepatocellular carcinoma cells HepG-2. The most cytotoxic compound was ME-GA (18ß-Glycyrrhetinic-30-methyl ester) with no cytotoxic effect on the normal cell line. In summary, this new derivative may be used as an alternative or complementary medicine for liver cancer.


Assuntos
Antineoplásicos/química , Carcinoma Hepatocelular/tratamento farmacológico , Ácido Glicirrízico/química , Neoplasias Hepáticas/tratamento farmacológico , Antineoplásicos/síntese química , Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Ensaios de Seleção de Medicamentos Antitumorais , Ácido Glicirretínico/química , Ácido Glicirrízico/análogos & derivados , Ácido Glicirrízico/síntese química , Ácido Glicirrízico/farmacologia , Células Hep G2 , Humanos , Estrutura Molecular , Relação Estrutura-Atividade , Triterpenos/química
2.
Bioorg Khim ; 30(2): 168-73, 2004.
Artigo em Russo | MEDLINE | ID: mdl-15143672

RESUMO

New amino acid derivatives of glycyrrhizic acid and its methyl ester were selectively synthesized using active N-succinimide esters. The compounds with residues of glycine ethyl ester and alanine methyl and butyl esters increased the level of agglutinins and hemolysins in blood serum of mice two- to threefold in comparison with the control upon parenteral administration at a dose of 2 mg/kg for 14 days. The English version of the paper: Russian Journal of Bioorganic Chemistry, 2004, vol. 30, no. 2; see also http://www.maik.ru.


Assuntos
Adjuvantes Imunológicos/síntese química , Adjuvantes Imunológicos/farmacologia , Glicopeptídeos/química , Ácido Glicirrízico/síntese química , Ácido Glicirrízico/farmacologia , Adjuvantes Imunológicos/química , Animais , Éteres/química , Ácido Glicirrízico/química , Camundongos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA